Compare TUYA & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TUYA | SLDB |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2021 | 2017 |
| Metric | TUYA | SLDB |
|---|---|---|
| Price | $1.87 | $10.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $3.49 | ★ $16.36 |
| AVG Volume (30 Days) | 544.3K | ★ 816.0K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.40% | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,094,000.00 |
| Revenue This Year | $13.76 | N/A |
| Revenue Next Year | $11.90 | N/A |
| P/E Ratio | $27.45 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.61 | $3.79 |
| 52 Week High | $2.73 | $11.45 |
| Indicator | TUYA | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 59.65 | 62.71 |
| Support Level | $1.87 | $5.21 |
| Resistance Level | $1.97 | $11.45 |
| Average True Range (ATR) | 0.06 | 0.43 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 76.35 | 90.46 |
Tuya Inc is an AI cloud platform service provider dedicated to bringing AI into everyday life. The group leverages its TuyaOpen open-source framework and universal AI Agent engines, including the AI Agent development platform, to integrate multimodal AI capabilities and reduce barriers to AI development. It drives the adoption of AI-powered lifestyles and speeds up the integration of AI with the physical world. It offers physical AI solutions for smart devices, commercial use, and industry developers using cloud computing and spatial intelligence. It builds a developer community that collaborates to create smart solutions grounded in sustainability, security, efficiency, agility, and openness. All the Group's revenue are derived from within the PRC.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.